Pragmatic clinical trials in CKD: Opportunities and challenges

Journal of the American Society of Nephrology

Volumn 27, Issue 10, 2016, Pages 2948-2954

  De Boer, Ian H ^a   Kovesdy, Csaba P ^b,c   Navaneethan, Sankar D ^d,e   Peralta, Carmen A ^f,g   Tuot, Delphine S ^h   Vazquez, Miguel A ⁱ   Crews, Deidra C ^j  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Kidney Health Research Collaborative   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

ACCESS TO INFORMATION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL PROTOCOL; DISEASE REGISTRY; ELECTRONIC HEALTH RECORD; END STAGE RENAL DISEASE; EXTERNAL VALIDITY; HEALTH EDUCATION; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFORMED CONSENT; KIDNEY TRANSPLANTATION; MEDICAL ETHICS; NEPHROLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING TEST; SELF CARE; STUDY DESIGN; RENAL INSUFFICIENCY, CHRONIC; STANDARDS;

HUMANS; PRAGMATIC CLINICAL TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 85019924490     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015111264     Document Type: Review

References (49)

1. Hill AB: The Environment and Disease: Association or Causation? Proc R Soc Med 58: 295-300, 1965
2. Organization, review, and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Control Clin Trials 9: 137-148, 1988
3. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1887-1892, 2000
4. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185, 2003
5. Clancy C, Collins FS: Patient-Centered Outcomes Research Institute: The intersection of science and health care. Sci Transl Med 2: 37cm18, 2010
6. DeMets DL, Califf RM: A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 305: 713-714, 2011
7. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD: The landscape of clinical trials in nephrology: A systematic review of Clinicaltrials.gov. Am J Kidney Dis 63: 771-780, 2014
8. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, MolnarMZ, Morgenstern H, Nallamothu B, O'Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 66: S1-305, 2015
9. Després JP, Nadeau A, Tremblay A, Ferland M,Moorjani S, Lupien PJ, ThériaultG, Pinault S, Bouchard C: Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38: 304-309, 1989
10. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A populationbased study of potential explanatory factors. J Am Soc Nephrol 13: 2363-2370, 2002
11. Volkova N, McClellan W, Klein M, Flanders D, Kleinbaum D, Soucie JM, Presley R: Neighborhood poverty and racial differences in ESRD incidence. J Am SocNephrol 19: 356-364, 2008
12. Kovesdy CP, Anderson JE: Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 20: 566-569, 2007
13. Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20: 637-648, 1967
14. Macpherson H: Pragmatic clinical trials. Complement Ther Med 12: 136-140, 2004
15. Patsopoulos NA: A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 13: 217-224, 2011
16. GodwinM, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, Lam M, Seguin R: Pragmatic controlled clinical trials in primary care: The struggle between external and internal validity. BMC Med Res Methodol 3: 28, 2003
17. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290: 1624-1632, 2003
18. 2016. Available at: http://sites.duke.edu/rethinkingclinicaltrials/. Accessed March 17, 2016
19. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1: 397-402, 1986
20. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M: The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 350: h2147, 2015
21. Drawz PE, Archdeacon P, McDonald CJ, Powe NR, Smith KA, Norton J, Williams DE, Patel UD, Narva A: CKD as a Model for Improving Chronic Disease Care through Electronic Health Records. Clin J Am Soc Nephrol 10: 1488-1499, 2015
22. Collins FS, Varmus H: A new initiative on precision medicine. N Engl J Med 372: 793-795, 2015
23. Schillinger D. Literacy and health communication: reversing the 'inverse care law'. Am J Bioeth 7:15-18, 2007
24. FarmerDF, Jackson SA,Camacho F,HallMA: Attitudes of African American and low socioeconomic status white women toward medical research. J Health Care Poor Underserved 18: 85-99, 2007
25. Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D: More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved 21: 879-897, 2010
26. UyBico SJ, Pavel S, Gross CP: Recruiting vulnerable populations into research: A systematic review of recruitment interventions. J Gen Intern Med 22: 852-863, 2007
27. Estrella MM, Jaar BG, Cavanaugh KL, Fox CH, Perazella MA, Soman SS, Howell E, Rocco MV, Choi MJ; National Kidney Foundation: Perceptions and use of the national kidney foundation KDOQI guidelines: A survey of U.S. renal healthcare providers. BMC Nephrol 14: 230, 2013
28. Abdel-Kader K, Greer RC, Boulware LE, Unruh ML: Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: A survey study. BMC Nephrol 15: 64, 2014
29. Diamantidis CJ, Powe NR, Jaar BG, Greer RC, Troll MU, Boulware LE: Primary carespecialist collaboration in the care of patients with chronic kidney disease. Clin J Am Soc Nephrol 6: 334-343, 2011
30. Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Konig V, Burrucker YK, Hyland J, Dann P, Tucky BH, Sharp JW, Nally JV: Development of a chronic kidney disease patient navigator program. BMC Nephrol 16: 69, 2015
31. Mendu ML, Schneider LI, Aizer AA, Singh K, Leaf DE, Lee TH,Waikar SS: Implementation of a CKD checklist for primary care providers. Clin J Am Soc Nephrol 9: 1526-1535, 2014
32. Fox CH, Vest BM, Kahn LS, Dickinson LM, Fang H, Pace W, Kimminau K, Vassalotti J, Loskutova N, Peterson K: Improving evidence-based primary care for chronic kidney disease: study protocol for a cluster randomized control trial for translating evidence into practice (TRANSLATE CKD). Implement Sci 8: 88, 2013
33. Cooney D, Moon H, Liu Y, Miller RT, Perzynski A,Watts B, Drawz PE: A pharmacist based intervention to improve the care of patients with CKD: A pragmatic, randomized, controlled trial. BMC Nephrol 16: 56, 2015
34. Crews DC, Greer RC, Fadrowski JJ, Choi MJ, DoggettD, Segal JB, FawoleKA, Crawford PR, Boulware LE: Setting an agenda for comparative effectiveness systematic reviews in CKD care. BMC Nephrol 13: 74, 2012
35. Tong A, Crowe S, Chando S, Cass A, Chadban SJ, Chapman JR, Gallagher M, Hawley CM, Hill S, Howard K, Johnson DW, Kerr PG, McKenzie A, Parker D, Perkovic V, Polkinghorne KR, Pollock C, Strippoli GF, Tugwell P,Walker RG,Webster AC,Wong G, Craig JC: Research Priorities in CKD: Report of a National Workshop Conducted in Australia. Am J Kidney Dis 66: 212-222, 2015
36. Platt R, Kass NE, McGraw D: Ethics, regulation, and comparative effectiveness research: time for a change. JAMA 311: 1497-1498, 2014
37. Pletcher MJ, Lo B, Grady D: Informed consent in randomized quality improvement trials: A critical barrier for learning health systems. JAMA Intern Med 174: 668-670, 2014
38. Chalil Madathil K, Koikkara R, Obeid J, Greenstein JS, Sanderson IC, Fryar K, Moskowitz J, Gramopadhye AK: An investigation of the efficacy of electronic consenting interfaces of research permissions management system in a hospital setting. Int J Med Inform 82: 854-863, 2013
39. Nayak RK, Wendler D, Miller FG, Kim SY: Pragmatic Randomized Trials Without Standard Informed Consent?: A National Survey. Ann Intern Med 163: 356-364, 2015
40. Cho MK, Magnus D, Constantine M, Lee SS, Kelley M, Alessi S, Korngiebel D, James C, Kuwana E, Gallagher TH,DiekemaD, Capron AM, Joffe S, Wilfond BS: Attitudes Toward Risk and Informed Consent for Research on Medical Practices: A Cross-sectional Survey. Ann Intern Med 162: 690-696, 2015
41. Sugarman J, Califf RM: Ethics and regulatory complexities for pragmatic clinical trials. JAMA 311: 2381-2382, 2014
42. Reisin E, Harris RC, Rahman M: Commentary on the 2014 BP guidelines from the panel appointed to the Eighth Joint National Committee (JNC 8). J Am Soc Nephrol 25: 2419-2424, 2014
43. Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, ChertowGM: Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clin J Am Soc Nephrol 11: 539-546, 2016
44. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, Safford MM, Zhang X, Muntner P, Warnock D: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to endstage renal disease and mortality. JAMA 305: 1545-1552, 2011
45. Fujioka S,Matsuzawa Y, Tokunaga K, Tarui S: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54-59, 1987
46. Amarasingham R, Moore BJ, Tabak YP, Drazner MH, Clark CA, Zhang S, Reed WG, Swanson TS, Ma Y, Halm EA: An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care 48: 981-988, 2010
47. Amarasingham R, Velasco F, Xie B, Clark C, Ma Y, Zhang S, Bhat D, Lucena B, Huesch M, Halm EA: Electronic medical record-based multicondition models to predict the risk of 30 day readmission or death among adult medicine patients: validation and comparison to existing models. BMC Med Inform Decis Mak 15: 39, 2015
48. Bosworth C, de Boer IH: Impaired vitamin D metabolism in CKD. SeminNephrol 33: 158-168, 2013
49. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL, Wheeler DC, Leonard MB: Revisiting KDIGO clinical practice guideline on chronic kidney diseasemineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 87: 502-528, 2015